Phase 1, first-in-human study investigati... - Cure Parkinson's

Cure Parkinson's

26,583 members27,900 posts

Phase 1, first-in-human study investigating the safety, tolerability, & pharmacokinetics of CVN424 a GPR6 inverse agonist

0 Replies

A new study reports the results of Phase 1, a first-in-human study investigating the safety, tolerability, & pharmacokinetics of CVN424 (a GPR6 inverse agonist being developed by cerevance for Parkinson's) in healthy volunteers.

jpet.aspetjournals.org/cont...

results

"A total of 64 subjects were enrolled, 48 received CVN424 (30 in the SAD cohorts and 18 in the

MAD cohorts), and 16 received placebo (10 in the SAD cohorts and 6 in the MAD cohorts). One

MAD subject who received 75 mg dose of CVN424 discontinued early because of an adverse

event of dysphagia; all other subjects completed the study as per protocol."

Not what you're looking for?

You may also like...

Positive results for Cerevance’s Parkinson’s drug, phase 2 of CVN424 a GPR6 inverse agonist

In phase 2 trials, the drug reduced ‘OFF time’ which refers to periods of the day when Parkinson’s...

Results of a Phase 1b trial of MODAG's oligomer modulator anle138b evaluating the safety tolerability in healthy volunteers

Results of a Phase 1b randomised, double-blind, placebo-controlled clinical trial evaluating the...

is this our MIRACLE?! ...REMINDER for WEBINAR! PD-Medical Research Study- First Look at the Data from Intranasal Delivery of FGF-1

Parkinson's Disease-Medical Research Study- First Look at the Data from Intranasal Delivery of...

Encouraging results from the phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in PD

Highlights • Oral NR increases brain NAD levels in individuals with Parkinson’s disease • NR...

Low White Blood Cell Counts May Indicate Early Stages of Parkinson’s

I have not been diagnosed with PD. I have RBD and a sore shoulder and leg and a poor sense of...